Development of dermal compounds for the pharmaceutical market can require diff ering approaches, depending on whether the compound is a new chemical entity (NCE) or a formulation of a previously marketed drug. In today’s research environment, developing a dermal NCE generally follows the same path as other small molecule NCEs administered orally or systemically, except that the dermal route is used in a non-rodent model. Rodent models can be used for systemic evaluations (e.g., subcutaneous, oral) to provide potential systemic toxicity data. Rodent models can employ a systemic route (e.g., subcutaneous, oral) to provide potential systemic toxicity data. This article will touch on a few points regarding dermal studies in the non-rodent model.